T cell directed therapies – National myeloma month 2023

In this webinar, Professor Joy Ho explains T-cell–directed therapies in multiple myeloma, focusing on CAR T-cell therapy and bispecific antibodies.

She breaks down how these treatments work, how CAR T cells are manufactured and delivered, and reviews recently published clinical trial results in relapsed/refractory myeloma—highlighting response rates, durability, and survival outcomes. Professor Ho also covers key safety issues including cytokine release syndrome (CRS), neurotoxicity (ICANS), infections, and cytopenias, and discusses practical questions around access, sequencing treatments, and what happens when therapy stops working. The session also highlights major Australian trial activity and how these therapies may move earlier in treatment over time.

Watch on YouTube

Keep watching

Watch our other webinars